As the workweek comes to an end, U.S. drugmakers and biotechs are reconsidering their reliance on Chinese partners for manufacturing, research, and ingredients due to rising geopolitical tensions. Companies like AstraZeneca and Amicus Therapeutics are seeking alternatives to reduce China risk, despite the lower costs associated with Chinese work. In contrast, a study found that Canada is 40% less likely to experience drug shortages compared to the U.S., attributed to the approach taken by the Canadian government to address supply chain issues. The difference in shortage rates highlights the importance of proactive regulatory measures in preventing actual shortages.
Source link
Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more
